LY 4395089
Alternative Names: LY-4395089Latest Information Update: 21 May 2026
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease; Ulcerative colitis
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 18 May 2026 Eli Lilly and Company plans a phase I pharmacokinetics trial (In volunteers) in USA (PO) in May 2026 (NCT07592572)
- 04 May 2026 Phase-II clinical trials in Crohn's disease (Treatment-resistant, Combination therapy) in USA (PO) (NCT07483073)
- 04 May 2026 Phase-II clinical trials in Ulcerative colitis (Treatment-resistant, Combination therapy) in USA (PO) (NCT07483073)